- mAbxience will hold the marketing authorization, while Abiogen Pharma will manage commercialization and marketing activities in Italy.
- This partnership combines mAbxience’s expertise in biosimilar development with Abiogen Pharma’s strong presence and commercial capabilities in the Italian market.
Madrid, Spain, May 26th, 2025 — mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Abiogen Pharma today announced a new strategic licensing agreement to develop and commercialize a biosimilar candidate in Italy.
Under the terms of this agreement, mAbxience will hold the marketing authorization for the biosimilar candidate, while Abiogen Pharma will be responsible for all commercialization and marketing activities in Italy. This collaboration combines mAbxience’s expertise in biosimilar development with Abiogen Pharma’s strong presence and commercial capabilities in the Italian market.
“We are thrilled to partner with Abiogen Pharma to bring this biosimilar candidate to patients in Italy. Our collaboration reflects mAbxience’s commitment to delivering high-quality, accessible therapies across various geographies,” said José Ramón Millán, Global Partnering & Portfolio Director at mAbxience.
“This agreement is part of a broader, long-term strategic path for us,” said Prisca Di Martino, Chief Commercial Officer at Abiogen Pharma. “It reflects our dedication to therapeutic areas where we bring deep expertise. Partnering with mAbxience supports our goal to expand access to advanced biologic therapies in Italy. This is another step towards innovative, sustainable solutions for patients and healthcare systems.”
This agreement marks another milestone in mAbxience’s strategy to provide affordable, life-saving therapies worldwide. Both mAbxience and Abiogen Pharma expect that this partnership will enhance patient access to advanced treatments, while also helping healthcare systems manage the rising costs of biologic therapies.
About Abiogen Pharma
Abiogen Pharma is headquartered in Pisa, Italy. Since 1997, its business spans across several integrated areas: research and development, manufacturing of pharmaceuticals with its own brand or under third-party contracts, and marketing of own and licensed drugs. Its target therapeutic areas include bone metabolism, pain treatment, as well as respiratory, metabolic (diabetes) and dermatological disorders. The company’s production plant, with over 10,000 sqm dedicated, combines decades of pharmaceutical expertise with cutting-edge technology. This solid industrial foundation has enabled Abiogen Pharma to accelerate its international expansion, now covering Germany and Switzerland through the acquisitions of the companies Altamedics and EffRx. With over €180 million in revenue (2023) and nearly 500 employees at group level, Abiogen Pharma ranks among the 15 largest Italian pharmaceutical companies.
Please visit our website (www.abiogen.it) or connect with us on LinkedIn.
About mAbxience
mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. In August 2022, Fresenius Kabi and Insud Pharma entered into an agreement whereby Fresenius Kabi, an operating company of Fresenius, acquired a majority stake of mAbxience, making it a global, vertically integrated biotechnology company. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization services (CDMO), utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website (www.mabxience.com) or connect with us on LinkedIn.
